Fda approves acetadote® snda

- new dosing regimen simplifies administration - nashville, tenn. , dec. 9, 2024 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the fda has approved a supplemental new drug application (snda) for its acetadote® (n-acetylcysteine for injection) product.

CPIX Ratings Summary

CPIX Quant Ranking